Exhibit 99.2

® Xencor Q3 2022 Financial Results XmAb®564 Data Presentation November 7, 2022

2 Speakers Bassil Dahiyat, Ph.D. President Chief Executive Officer Director John Kuch Senior Vice President & Chief Financial Officer John Desjarlais, Ph.D. Senior Vice President Chief Scientific Officer Allen Yang, M.D., Ph.D. Senior Vice President Chief Medical Officer Ralph Zitnik, M.D. Executive Medical Director

3 Forward - Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trials; the plans and objectives of management for future operations; and the potential markets for Xencor's product and development candidates. Forward - looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and involve numerous risks and uncertainties, many of which are beyond Xencor's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward - looking statements. Such risks include, but are not limited to, potential delays in development timelines or negative preclinical or clinical trial results, reliance on third parties for development efforts and changes in the competitive landscape including changes in the standard of care, as well as other risks described in Xencor's filings with the Securities and Exchange Commission (SEC). Xencor expressly disclaims any duty, obligation or undertaking to update or revise any forward - looking statements contained herein to reflect any change in Xencor's expectations with regard thereto of any subsequent change in events, conditions or circumstances on which any such statements are based, except in accordance with applicable securities laws. For all forward - looking statements, we claim the protection of the safe harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995.

4 Agenda for Today’s Call 2 1 3 Recent Business Updates and Financial Results XmAb ® 564 Data Presentation Q&A

® XmAb®564 Single Dose Phase 1a Data Presentation Reduced potency IL2 - Fc For selective expansion of regulatory T cells In development for patients with autoimmune diseases

6 XmAb® Cytokines: Potency - tuned to Enhance Half - life and Tolerability Native cytokine XmAb potency - optimized cytokine - Fc Toxicity Activity Time → Xencor’s general approach for creating cytokine therapies • Overcomes native cytokine short half - life and high toxicity • Systematically engineer a broad portfolio of cytokines Reduced affinity • Receptor selectivity • ↑Half - life XmAb Fc • ↑Half - life • ↑Stability • Modular Potency reduced for optimal PK/PD Potency

7 XmAb®564 Phase 1a Clinical Trial Top - line Data Summary • Single ascending dose of subcutaneously administered XmAb564 in healthy volunteers • Well tolerated; no serious adverse events or dose limiting toxicities observed • Selective expansion of CD25 bright regulatory T cells (Tregs) of 10x and higher beginning at 3 rd dose level and reaching 117x increase over baseline at highest dose • Exceptional durability of Treg expansion relative to reported third - party data • Provides opportunity to explore differentiated multi - week dosing schedules • Minimal increases in natural killer (NK) cells and conventional T cells ( Tcons ) Second potency - tuned XmAb Cytokine program showing marked target cell expansion and good tolerability in human clinical trials • XmAb306, an IL15 - IL15R a - Fc fusion in oncology, showed consistent and robust dose - dependent NK cell expansion and accumulation upon repeat dosing, reaching 40 - 100x higher than baseline in higher dose cohorts (Nov. 2021)

8 Tregs Important Role in Homeostasis and in Autoimmune Disease • Regulatory T cells (Tregs) are CD4 + FoxP3 + cells expressing CD25 (IL - 2R α ) that maintain immune tolerance in tissues by suppressing the function of both CD4 and CD8 effector T cells • Tregs are dysfunctional in most autoimmune diseases • A therapeutic approach has been to restore Treg numbers and function via a low - dose IL - 2 regimen • Treg homeostasis depends on IL - 2 • IL - 2 as a drug suffers from fast in vivo clearance and a narrow therapeutic index APCs Teffs Tregs B cells NK cells

9 IL - 2 Activates Multiple T Cell Types XmAb564 is Engineered to Improve for Treg Selectivity Overall 400 - 1000x reduced potency 2x increase to CD25 (IL2R α ) binding and reduced affinity for IL2R β Heterodimeric Fc with Xtend ™ No effector function IL2 Monovalent to avoid undesired activation Tcon = conventional T cell Tcons IL2R β CD25 (IL2R α ) IL2R γ Tregs NK cells WT = wild - type

10 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 0 1000 2000 3000 Concentration (pM) pSTAT5 MFI CD4+CD45RA+ CD4+CD45RA- Tregs CD8+CD45RA+ CD8+CD45RA- Gamma Delta Cells CD56+ NK cells XmAb564 Design Reduces Potency and Improves Treg Selectivity XmAb564 exhibits extended half - life and good tolerability in NHPs (not shown) Drug conc. (ng/mL) Days Sustained PK up to Several Days in Non - Human Primates Recombinant human WT IL - 2 XmAb564 w/o Xtend ™ XmAb564 Selectively Promotes Treg Signaling in Human T Cells XmAb564 selectively promotes Tregs and has extended half - life due to low potency and Xtend ™ Fc domain 10 -4 10 -3 10 -2 10 -1 10 0 10 1 10 2 10 3 10 4 0 1000 2000 3000 4000 Concentration (pM) pSTAT5 MFI CD4+CD45RA+ CD4+CD45RA- Tregs CD8+CD45RA+ CD8+CD45RA- Gamma Delta Cells CD56+ NK cells

11 XmAb564 Phase 1a Healthy Volunteer Study Design Phase 1a single - ascending dose (SAD) study • Randomized and double - blinded • Subcutaneous administration of XmAb564 • Heathy volunteers (n=48) • 6 dose level cohorts • Randomized 6:2 (XmAb564:placebo) Outcome measures • Safety and tolerability • Pharmacokinetics and activity biomarkers (e.g., T - cell populations) 0.003 mg/kg n=6 0.007 mg/kg n=6 0.015 mg/kg n=6 0.025 mg/kg n=6 0.04 mg/kg n=6 0.065 mg/kg n=6 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 P n=2 P n=2 P n=2 P n=2 P n=2 P n=2 Placebo n=12 XmAb564 n=36

12 XmAb564 Was Well Tolerated Well tolerated including at the highest dose evaluated (0.065 mg/kg) • All adverse events (AEs) were grade 1 or 2 (mild - to - moderate) and self - limited • Injection site reaction was the most reported AE • No serious AEs, dose - limiting toxicities or early discontinuations due to AEs • No clinically significant abnormalities in laboratory values, vital signs and ECGs Laboratory findings and pharmacokinetics • Some subjects had transient, reversible elevations in blood eosinophils • No eosinophil - related AEs were observed • Possibly related to mechanism - of - action, reported in other third - party CD25 - targeting IL - 2 programs • No other clinically significant abnormalities in safety laboratory studies were observed • Terminal half - life is estimated to be 9 - 10 days at lower doses and 6 - 7 days at the highest dose, consistent with an increase in CD25 target - mediated clearance on the expanding Treg population Study remains blinded

13 117x 10x 32x 2x ** ** ** ** ** * 21x 6x 6x XmAb564 Promotes Robust & Durable Expansion of CD25 bright Tregs Numeric values in “Peak Fold Change” plot are Mean 1 Peak fold change: Peak CD25 bright FoxP3 + CD4 Treg cell absolute count at a post - treatment time point divided by absolute count at baseline NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test Durable, dose - dependent increases in CD25 bright Tregs Highest reported CD25 bright Treg expansion Peak Fold Change 1 Time Course Absolute Counts (per μ l) Treg baseline counts are low integer values, leading to between group variability in fold change calculations 117 - fold mean peak expansion over baseline in Cohort 6

14 0.14 0.04 0.03 0.02 0.01 0.01 0 *** *** *** *** ** * XmAb564 Promotes Robust & Durable Increases in CD25 bright Treg/ Tcon ratio Treg baseline counts are not used in Treg/ Tcon ratio calculations, leading to less variability in ratio values Time Course Peak Ratio Numeric values in “Peak Fold Change” plot are Mean Dashed horizontal blue line represents the average of pre - dose values from all 48 subjects with ± 2SD shown in grey lines NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test

15 8x 2x 4x 3x ** * 5x 2x 3x XmAb564 Promotes Robust & Durable Expansion of Total Tregs Numeric values in “Peak Fold Change” plot are Mean 1 Peak fold change: Peak CD25 + FoxP3 + CD4 Treg cell absolute count at a post - treatment time point divided by absolute count at baseline NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test Treg baseline counts are low integer values, leading to between group variability in fold change calculations Time Course Peak Fold Change 1

16 145 26 16 24 33 11 11 *** 65 8 6 ** ** 10 3 3 2 CD25 bright and Total Treg Remain Elevated for at Least 3 Weeks Day 21 CD25 bright Treg Cell Count CD25 hi FoxP3 + CD4 + Numeric values in plots are Mean NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test Day 21 Total Treg Cell Count CD25 + FoxP3 + CD4 + **

17 XmAb564 Induces Minimal Increases in Conventional T cells and NK Cells CD56 + NK Cell Count CD8 + Tcon Cell Count CD4 + Tcon Cell Count Dashed horizontal blue line represent the average of pre - dose values from all 48 subjects with ± 2SD shown in grey lines

18 XmAb564 Phase 1a Topline Summary XmAb564 is well tolerated and generates a durable, dose - dependent and selective expansion of Tregs with a single dose • 117 - fold mean peak expansion over baseline in CD25 bright Tregs and 8 - fold mean peak expansion in total Tregs at highest dose • Marked elevation of Tregs sustained through at least day 21: CD25 bright and total Tregs increased 44 - fold and 4.5 - fold at highest dose, respectively • Treg/ Tcon ratio increased significantly in a dose - dependent manner • All AEs Grade 1/2 and resolved without intervention Phase 1b study in patients • First patient dosed in a newly initiated Phase 1b, multiple - ascending dose (MAD) study of XmAb564 in patients with atopic dermatitis and psoriasis • Multiple dosing schedules to be explored based on pharmacodynamic data

19 Xencor’s Growing Portfolio of Potency - Optimized XmAb® Cytokines Second validation of Xencor’s approach to cytokine therapeutics • XmAb306 (IL - 15) Phase 1 demonstrated 40 - to 100 - fold increases in activated NK cells and accumulation upon multiple doses • In two first - in - human studies, reduced potency and long half - life has translated to improved tolerability compared to the high toxicities generated by native cytokines XmAb Cytokines • Engineered to expand select immune cell populations • Designed to be tolerable, active and easy to use IL - 15/IL - 15R a XmAb306 Phase 1 IL - 2 (Treg selective) XmAb564 Phase 1b IL12 - p40/IL12 - p35 XmAb662 Phase 1 in 2023 Decoy resistant IL - 18 Preclinical stages LAG3 - targeted IL - 15 Preclinical stages Native cytokine XmAb potency - optimized cytokine - Fc Toxicity Activity Time → WHOLLY OWNED GENENTECH COLLABORATION 45% Xencor economics

® Q&A

® Data Appendix

22 *** 82.3x 16.7x 16.7x *** ** 8.5x 5.7x 5.1x 2.1x *** ** Peak Fold Induction of CD25 bright and Total Treg Cells Shows Consistent Dose Response of Treg Populations to XmAb564 Total Treg Peak Fold Induction 1 CD25 + FoxP3 + CD4 + Numeric value in “Peak Fold Change” plot is Mean 1 Peak fold induction: Peak CD25 bright Treg or total Treg cell absolute counts of each subject divided by the average of all pre - dose values from all subjects (n=48) NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test 10.7x 3.2x 2.9x 2.0x *** 2.4x 1.7x 1.7x Treg Peak Fold Induction 1 CD25 hi FoxP3 + CD4 +

23 Ratio of CD25 bright / Tcon and Total Treg/ Tcon Peak Fold Induction Shows Consistent Dose Response of Treg Populations to XmAb564 Numeric value in “Peak Fold Change” plot is Mean Peak fold induction: Peak CD25 bright Treg/ Tcon or total Treg/ Tcon ratios of each subject divided by the average of all pre - dose values from all subjects (n=48) NS: p>0.05, *: p≤0.05, **: p≤0.01, ***:p≤0.001 compared with placebo treated cohort, Wilcoxon test 7.3x 3.7x 2.5x 2.0x 1.6x 1.9x 1.8x *** *** *** *** 56.9x 17.5x 14.1x 6.7x 4.4x 5.4x 1.9x *** *** ** * CD25 bright Treg/ Tcon Peak Fold Induction CD25 hi FoxP3 + CD4 + Total Treg/ Tcon Peak Fold Induction CD25 + FoxP3 + CD4 +